Certolizumab pegol in rheumatoid arthritis: current update.
Expert Opin Biol Ther
; 14(6): 841-50, 2014 Jun.
Article
de En
| MEDLINE
| ID: mdl-24654999
ABSTRACT
INTRODUCTION:
The development of TNF-α inhibitors (TNF-is) represents a major advancement in the treatment of rheumatoid arthritis (RA). Currently, there are five agents licensed for moderate-to-severely active RA. Certolizumab pegol (CZP) is a novel PEGylated, constant fragment-free TNF-i therapy, which is the focus of this review. AREAS COVERED Data from Phase III randomised controlled trials in terms of clinical efficacy, radiographic progression, patient-reported outcomes and safety profile are reviewed. These include long-term data from open-label extension studies. EXPERT OPINION The advantages of CZP include rapid reduction of disease activity, low rates of injection-site reaction and may be safe for use in pregnancy. The long-term data strengthen the position of CZP for use either as monotherapy or preferably in combination with disease modifying anti-rheumatic drugs (DMARDs), in moderate-to-severely active RA, comparable to other TNF-is. Notably, prolonged CZP exposure is not associated with increased risk of severe infection compared to general population, contrasting with preliminary analysis of short-term data. Over the next few years, evidence will be available on the use of CZP in combination with methotrexate for remission induction in DMARD-naïve patients, biomarkers and the development and licensing of TNF-i biosimilars.Mots clés
Texte intégral:
1
Collection:
01-internacional
Base de données:
MEDLINE
Sujet principal:
Polyéthylène glycols
/
Polyarthrite rhumatoïde
/
Fragments Fab d'immunoglobuline
/
Antirhumatismaux
/
Anticorps monoclonaux humanisés
Type d'étude:
Clinical_trials
/
Diagnostic_studies
Aspects:
Patient_preference
Limites:
Animals
/
Humans
Langue:
En
Journal:
Expert Opin Biol Ther
Sujet du journal:
BIOLOGIA
/
TERAPEUTICA
Année:
2014
Type de document:
Article